Jacobs Levy Equity Management Inc. Invests $2.48 Million in Dynavax Technologies Corporation $DVAX

Key Points

• Jacobs Levy Equity Management Inc. has acquired a new stake in Dynavax Technologies Corporation, purchasing 191,005 shares valued at approximately $2.48 million.
• Institutional investors own a significant 96.96% of the company, indicating strong interest in Dynavax's stock.
• Analysts maintain a consensus rating of "Moderate Buy" for Dynavax, with a target price of approximately $24.33, highlighting positive investor sentiment.

Jacobs Levy Equity Management Inc. acquired a new position in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 191,005 shares of the biopharmaceutical company's stock, valued at approximately $2,477,000. Jacobs Levy Equity Management Inc. owned approximately 0.16% of Dynavax Technologies as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of DVAX. Choreo LLC raised its position in shares of Dynavax Technologies by 3.2% in the 1st quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company's stock valued at $452,000 after buying an additional 1,065 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Dynavax Technologies by 4.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company's stock valued at $401,000 after buying an additional 1,453 shares in the last quarter. Parkman Healthcare Partners LLC grew its holdings in shares of Dynavax Technologies by 0.7% during the 4th quarter. Parkman Healthcare Partners LLC now owns 220,980 shares of the biopharmaceutical company's stock valued at $2,822,000 after purchasing an additional 1,529 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Dynavax Technologies by 2.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,796 shares of the biopharmaceutical company's stock valued at $1,083,000 after purchasing an additional 2,206 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Dynavax Technologies during the 1st quarter valued at approximately $30,000. Institutional investors and hedge funds own 96.96% of the company's stock.

Insiders Place Their Bets

In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of Dynavax Technologies stock in a transaction on Friday, August 22nd. The shares were purchased at an average cost of $10.82 per share, with a total value of $41,116.00. Following the acquisition, the director directly owned 35,004 shares of the company's stock, valued at $378,743.28. The trade was a 12.18% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.98% of the stock is owned by insiders.

Dynavax Technologies Trading Down 3.4%

DVAX traded down $0.33 during trading on Friday, reaching $9.41. 1,650,058 shares of the company's stock were exchanged, compared to its average volume of 1,815,138. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $1.10 billion, a PE ratio of -20.46 and a beta of 1.24. The firm has a fifty day moving average price of $10.59 and a two-hundred day moving average price of $11.08.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The firm had revenue of $95.44 million for the quarter, compared to analyst estimates of $87.55 million. As a group, equities research analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 price target on shares of Dynavax Technologies in a report on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.